All Brands Owned by GSK plc

What does GSK own?
GSK owns a portfolio of prescription pharmaceuticals and vaccines. Its key products include Shingrix (shingles vaccine, GBP 3.6 billion in FY2025), Trelegy (respiratory, GBP 3.0 billion), the HIV franchise (GBP 7.7 billion including Dovato and Cabenuva), Arexvy (RSV vaccine), Nucala (respiratory), and Bexsero (meningitis vaccine). GSK previously owned consumer healthcare brands including Sensodyne, Advil, and Centrum, but these were spun off as Haleon plc in July 2022.

Is GSK publicly traded?
Yes, GSK plc is publicly traded on the London Stock Exchange and the New York Stock Exchange, both under the ticker symbol GSK. The company has a dispersed shareholder base dominated by institutional investors including BlackRock and Vanguard. GSK has been publicly traded since its formation in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

Who is the CEO of GSK?
Luke Miels became CEO of GSK on January 1, 2026, succeeding Dame Emma Walmsley. Miels previously served as GSK's Chief Commercial Officer. Walmsley led GSK for nearly nine years, oversaw the Haleon demerger, and steered the company through the Zantac litigation. She remains with the company until September 30, 2026 to support the transition.

Where is GSK headquartered?
GSK is headquartered in London, United Kingdom. The company's corporate offices are in Brentford, West London. GSK has major operations in the United States (approximately 15,000 employees), Europe, and emerging markets, with manufacturing facilities in the UK, U.S., Singapore, and India.

How many brands does GSK own?
GSK owns a portfolio of approximately 20 key prescription medicines and vaccines. The most significant by revenue are Shingrix, the HIV franchise (Dovato, Cabenuva, Juluca), Trelegy, Nucala, Arexvy, Bexsero, and oncology drugs Ojemda and Blenrep. The company does not own consumer healthcare brands, as these were spun off as Haleon in 2022.

Who owns GSK?
GSK is a publicly traded company with a dispersed shareholder base. No single shareholder controls the company. Major institutional investors include BlackRock, Vanguard Group, and other large asset management firms. The company is governed by a board of directors chaired by Sir Jonathan Symonds, with CEO Luke Miels responsible for day-to-day operations.

What was the Zantac litigation?
Zantac (ranitidine) was withdrawn from the U.S. market in 2020 after the FDA found that it contained NDMA, a probable carcinogen. Approximately 80,000 lawsuits were filed alleging Zantac caused cancer. GSK agreed in October 2024 to pay up to $2.3 billion to settle the U.S. claims without admitting liability. By the end of 2025, GSK had paid GBP 1.9 billion, with the remaining GBP 0.6 billion expected in 2026. The company described the settlement process as materially complete.